New immunotherapy combo shows promise in keeping high-risk childhood cancer at bay
NCT ID NCT03033303
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 30 times
Summary
This study tested a combination of Hu3F8 (an antibody) and GM-CSF (an immune booster) along with isotretinoin in 59 children with high-risk neuroblastoma who had achieved their first remission. The goal was to see if this immunotherapy could prevent the cancer from growing back. While the treatment may help control the disease, it does not offer a cure, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.